EGFR对食管癌同步放化疗敏感性预测价值的初步观察  

A preliminary study toward validating EGFR expression in esophageal carcinoma as used to predict the sensitivity to chemoradiotherapy

作　　者：李强[1] 杨哲[1] 赵瑛[1] 韩俊庆[1] 

机构地区：[1]山东大学附属省立医院肿瘤中心,济南250021

出　　处：《山东大学学报（医学版）》2012年第3期96-99,共4页Journal of Shandong University:Health Sciences

摘　　要：目的研究表皮生长因子受体(EGFR)对食管癌患者放化疗敏感性的预测作用。方法收集35例初治食管癌患者的病理组织,应用免疫组化SP法检测EGFR的表达情况,按是否存在EGFR过表达将所有患者分为2组,同时回顾性分析入组患者的同步放化疗效果,比较两组间的疗效差异。结果 EGFR阳性组与阴性组的同步放化疗完全缓解(CR)率分别为57.7%(15/26)以及11.1%(1/9),两组间差异有统计学意义(P=0.022)。结论EGFR可能有助于预测食管癌的同步放化疗敏感性。Objective To study the usefulness of EGFR expression as applied to predict the sensitivity to chemoradiotherapy in esophageal carcinoma.Method Tissue samples were collected from 35 esophageal cancer patients before any treatment was done.Immunohistochemistry was performed for EGFR.Chemoradiotherapy was carried about on all patients,and the sensitivity was reviewed against the immunohistochemical staining patterns.Result The complete response rate（CR） in the EGFR-positive group and EGFR-negative group was 57.7%（15/26）and 11.1%（1/9）,respectively,showing a significant difference（P=0.022）.Conclusion This observation suggests that EGFR expression level（YES vs NO） may help predict the sensitivity to chemoradiotherapy for esophageal carcinoma.

关 键 词：食管肿瘤 同步放化疗 表皮生长因子受体 敏感性 

分 类 号：R735.1[医药卫生—肿瘤]